Constance King

424 total citations
9 papers, 335 citations indexed

About

Constance King is a scholar working on Oncology, Molecular Biology and Cell Biology. According to data from OpenAlex, Constance King has authored 9 papers receiving a total of 335 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Molecular Biology and 2 papers in Cell Biology. Recurrent topics in Constance King's work include Cancer-related Molecular Pathways (6 papers), DNA Repair Mechanisms (5 papers) and Microtubule and mitosis dynamics (2 papers). Constance King is often cited by papers focused on Cancer-related Molecular Pathways (6 papers), DNA Repair Mechanisms (5 papers) and Microtubule and mitosis dynamics (2 papers). Constance King collaborates with scholars based in United States. Constance King's co-authors include Mark S. Marshall, Darlene Barnard, David A. Barda, Wayne Blosser, Jangsik Yang, Jung S. Yi, Richard P. Beckmann, Jack Dempsey, Samuel McNeely and Karen L. Cox and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and AIChE Journal.

In The Last Decade

Constance King

9 papers receiving 328 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Constance King United States	5	219	165	69	55	37	9	335
Han Liu China	14	182 0.8×	92 0.6×	43 0.6×	39 0.7×	15 0.4×	38	409
Shengjie Yin China	11	141 0.6×	56 0.3×	36 0.5×	45 0.8×	9 0.2×	22	373
Lu Xing China	13	221 1.0×	65 0.4×	38 0.6×	22 0.4×	11 0.3×	27	408
Patrick Metzger Germany	9	100 0.5×	47 0.3×	52 0.8×	23 0.4×	7 0.2×	31	254
Kathrin Michel Germany	9	196 0.9×	84 0.5×	16 0.2×	7 0.1×	30 0.8×	11	360
Chunxiao Zhu China	6	127 0.6×	76 0.5×	16 0.2×	27 0.5×	7 0.2×	19	279
Chuanjun Shu China	11	275 1.3×	78 0.5×	49 0.7×	11 0.2×	13 0.4×	32	463
Yuepeng Ke United States	8	228 1.0×	48 0.3×	34 0.5×	7 0.1×	15 0.4×	14	354
Zichang Yang China	11	244 1.1×	56 0.3×	20 0.3×	35 0.6×	8 0.2×	22	384

Countries citing papers authored by Constance King

Since Specialization

Citations

This map shows the geographic impact of Constance King's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Constance King with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Constance King more than expected).

Fields of papers citing papers by Constance King

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Constance King. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Constance King. The network helps show where Constance King may publish in the future.

Co-authorship network of co-authors of Constance King

This figure shows the co-authorship network connecting the top 25 collaborators of Constance King. A scholar is included among the top collaborators of Constance King based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Constance King. Constance King is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Wu, Wenjuan, Constance King, Gregory P. Donoho, et al.. (2018). Abstract 336: Anti-tumor activity of the Chk1 inhibitor prexasertib (LY2606368) as a single agent in triple negative breast cancer models. Cancer Research. 78(13_Supplement). 336–336. 4 indexed citations

Wu, Wenjuan, Shripad V. Bhagwat, Constance King, et al.. (2017). Abstract 317: Combination of a novel ERK1/2 inhibitor (LY3214996) with CDK4 and CDK6 inhibitor (abemaciclib) enhances antitumor efficacy in KRAS mutant non-small cell lung cancer (NSCLC). Cancer Research. 77(13_Supplement). 317–317. 1 indexed citations

King, Constance, Samuel McNeely, Darlene Barnard, et al.. (2015). LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms. Molecular Cancer Therapeutics. 14(9). 2004–2013. 139 indexed citations

Burkholder, Timothy P., Peter A. Lander, Matthew L. Brown, et al.. (2015). Design and synthesis of a novel series of [1-(4-hydroxy-benzyl)-1H-indol-5-yloxy]-acetic acid compounds as potent, selective, thyroid hormone receptor β agonists. Bioorganic & Medicinal Chemistry Letters. 25(7). 1377–1380. 8 indexed citations

Barnard, Darlene, Teresa F. Burke, Gregory P. Donoho, et al.. (2015). LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models. Investigational New Drugs. 34(1). 49–60. 19 indexed citations

King, Constance, Darlene Barnard, David A. Barda, et al.. (2013). Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Investigational New Drugs. 32(2). 213–226. 90 indexed citations

Marshall, Mark S., David A. Barda, Darlene Barnard, et al.. (2009). Abstract B248: Characterization and preclinical development of LCI-1, a selective and potent Chk1 inhibitor in phase 1 clinical trials. Molecular Cancer Therapeutics. 8(12_Supplement). B248–B248. 4 indexed citations

Marsh, S., George Somlo, H. L. McLeod, et al.. (2005). Pharmacogenetic analysis of paclitaxel in breast cancer. Journal of Clinical Oncology. 23(16_suppl). 3058–3058. 3 indexed citations

Yi, Jung S., Jangsik Yang, & Constance King. (2004). Water management along the flow channels of PEM fuel cells. AIChE Journal. 50(10). 2594–2603. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact